Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator Type of Study Phases of Clinical Trials for Drugs
N202604105 A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014) New Drug Phase Ⅲ
N202604115 A randomized, open-label (unblinding), crossover bioequivalence study to compare two dydrogesterone F.C. tablets in healthy female subjects under fasted state. New Medical Device NA
N202604120 A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment with Brenipatide in Delaying Time to Relapse Compared with Placebo in Adult Participants with Major Depressive Disorder (RENEWMDD-1) New Drug Phase Ⅲ
N202604145 A Phase 2b, Randomized, Placebo‑Controlled Study with Long-term Re-Treatment to Evaluate the Efficacy, Safety, and Tolerability of CBL‑514 Injection for Reducing Abdominal Subcutaneous Fat New Drug Phase Ⅲ
N202604152 Energy-Efficient Edge AI for Pervasive Health Monitoring: Self- Calibrating PPG Blood Pressure and Posture Analysis for Orthostatic Hypotension and Fall Prevention New Medical Device NA
N202605011 A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants with Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4) New Drug Phase Ⅲ
N202605012 First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations New Drug Phase Ⅰ
N202605040 Development and Validation of a Novel Generative AI-driven Digital Therapeutics Platform to Implement Personalized Cognitive Stimulation for Alzheimer's Disease: Year 2-4 Continuation Study Bioavailability / Bioequivalence (BA/BE) NA
N202605041 A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015) New Drug Phase Ⅱ
N202605047 Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection fraction and obesity (HF-POLARIS). New Drug Phase Ⅲ
1 2 21 22 23 24 25 26 27 31 32 / 32

TOP